Optimizing for the future: streamlining the production of T cell-based immunotherapies

Despite its high potential to treat rare conditions, T cell-based immunotherapy manufacturing faces challenges in terms of cost, quality/safety, standardization, scalability, and speed of innovation. This article explores the development of a 7-day, closed, viral-based CAR-T cell production process, and introduces a novel soluble transduction enhancer for optimizing lentiviral-based immunotherapy manufacturing. By improving scalability, reducing cytotoxicity, and enhancing CAR-T cell efficacy, this approach offers the potential to enable better outcomes for patients with cancers such as chronic lymphocytic leukemia, helping optimize both safety and cost-effectiveness in immunotherapy.